PRKDC and acute myeloid leukemia: Although we could not find studies specifically addressing the p53-dependent antitumor activity of a combination therapy involving a Topo II inhibitor and a DNA-PK inhibitor in solid tumor models, our hypothesis is supported by research conducted on acute myeloid leukemia (AML) cells.